Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Case Review: Lupus Patient with Acute Disseminating Encephalomyelitis

Teresa Sosenko, MD, Anca Musetescu, MD, PhD, Neha Gandhi, MD, Scott Friedstrom, MD, & Diana Girnita, MD, PhD  |  Issue: January 2018  |  January 19, 2018

The diagnosis of neuropsychiatric lupus often proves difficult and requires a multimodal approach due to overlapping characteristics with other factors, such as infections or metabolic abnormalities. Doctors must exclude alternative explanations for the signs and symptoms.

CSF analysis, imaging data and autoimmune workup help. In up to one-third of SLE cases, CSF analysis shows increased level of protein, decreased glucose and/or lymphocytic pleocytosis. These findings, however, are neither sensitive nor specific.4,5 Roughly 20 different anti­bodies have been detected in neuropsychiatric lupus, and this includes anti-ribosomal P antibodies and anti-N-methyl-D-aspartate receptor.4,5 Imaging, particularly MRI, proves especially useful, but many patients with SLE have some abnormalities detected on imaging.5

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

ADEM Discussion

ADEM, a fulminant demyelinating disease, is a monophasic disorder of the central nervous system. It’s rarely reported in adults. It’s most common in children because of immature myelin, the relative immaturity of the immune system and the increased frequency of infections seen in this age group.6 The incidence ranges from 0.4–0.8/100,000 per year.6,7,8,9 In approximately 30% of cases, ADEM progresses to multiple sclerosis (MS).10 Child mortality rates range from 10–30%, but most patients recover with minimal to no neurological disability.6,11,9,12

A 2015 study suggests infections trigger an immune response that causes disseminated multifocal inflammation and patchy demyelination.13 Neurologic symptoms such as fever and encephalopathy typically occur in ADEM from one to three weeks after the inciting event (which often is misleading because it resembles encephalitis) and progress rapidly.6,14 Other symptoms include weakness, ataxia, headache, meningismus, paresis, lethargy and seizures leading to coma.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Doctors can diagnose ADEM via clinical characteristics, laboratory findings and imaging features. CSF findings are abnormal in two thirds of cases and include pleocytosis and elevated protein.11 Oligoclonal bands are typically absent. Pathologic findings show prominent perivenous demyelination with infiltrates of lymphocytes and macrophages.11 CT scans are usually abnormal but nonspecific, and may show hypodense areas within cerebral white matter and juxtacortical areas.8

MRI remains the most useful tool for diagnosing ADEM. Typical MRI findings include widespread, bilateral, asymmetric increased signal intensity on T2 weighted imaging within the white and gray matter of the brain and spinal cord.6,8

Differential diagnoses include MS, encephalitis, optic neuritis and clinical isolated syndrome.11 The International Pediatric MS Study Group has proposed diagnostic criteria to discriminate ADEM from MS, which have been validated and used widely.6,8,14

There is no standard treatment for ADEM, but once the diagnosis is made, supportive care and high-dose IV methylprednisolone (10–30 mg/kg/day, up to 1 g/day) are imperative.11 Aggressive physical and occupational therapy are also essential to successful recovery. Alternative treatments include intravenous immunoglobulin and plasma exchange.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:ConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:ACR/ARHP Annual MeetingbrainClinicalDiagnosisdruglab testLupusmagnetic resonance imagingMRIoutcomepatient careprednisonepsychological disorderrheumatologistrheumatologySystemic lupus erythematosusTreatmentX-ray

Related Articles
    Atypical Giant Cell Arteritis Case Illustrates Diagnosis, Management Challenges

    Atypical Giant Cell Arteritis Case Illustrates Diagnosis, Management Challenges

    November 14, 2021

    Giant cell arteritis (GCA) is a granulomatous vasculitis of large- and medium-sized arteries, usually affecting the cranial branches of the aortic arch. It is the most common vasculitis, with the highest risk factor being age. Accurate diagnosis and prompt initiation of therapy are of great importance to prevent serious complications, with the most feared being…

    Susac’s Syndrome: Confusion, Expressive Aphasia, Gait Instability

    March 8, 2012

    A 49-year-old man presented to the hospital with confusion, dysarthria, expressive aphasia, and progressive gait instability.

    T Cells in Systemic Lupus Erythematosus

    August 1, 2011

    Progress toward targeted therapy

    Experts Discuss Proposed Giant Cell Arteritis Risk Tool

    April 26, 2018

    A proposed model to predict the risk of giant cell arteritis (GCA) prior to a temporal artery biopsy could help triage patients and guide decision making about the need for biopsy or monitoring (see Figure 1). There’s no specific biomarker for GCA, and GCA can be a “diagnostic conundrum, especially when it presents in an…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences